"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 17 Apr 2018 2:00 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administrator approved everoliums tablets for oral suspension (Afinitor Disperz; Novartis Pharmaceuticals) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. Read full press release.

  • 17 Apr 2018 1:52 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted approvals to nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

  • 27 Feb 2018 1:44 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved durvalumab (Infinzi; AstraZeneca) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read full press release

  • 27 Feb 2018 11:54 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved abermacicib (Verzeno; Eli Lilly) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Read full press release. 

  • 15 Feb 2018 9:18 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved apalutamide (Erleada; Janssen) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Read full press release. 

  • 08 Feb 2018 2:12 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved abiraterone acetate (Zytiga, Janssen Biotech, Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). Read full press release.

  • 12 Jan 2018 1:20 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza; AstraZeneca) a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Read full press release. 

  • 08 Jan 2018 2:32 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (Opdivo; Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Read full press release.

  • 08 Jan 2018 2:25 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug administration granted regular approval to pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. Read full press release.

  • 28 Nov 2017 9:43 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to obinutuzumab (Gazyva; Genentech) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II buly; III, or IV follicular lymphoma (FL). Read full press release.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software